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Xenogeneic chondrocytes and allogeneic mesenchymal stem cells (MSC) are considered 
a potential source of cells for articular cartilage repair. We here assessed the immune 
response triggered by xenogeneic chondrocytes when injected intraarticularly, as well as 
the immunoregulatory effect of allogeneic bone marrow-derived MSC after systemic admin-
istration. To this end, a discordant xenotransplantation model was established by injecting 
three million porcine articular chondrocytes (PAC) into the femorotibial joint of Lewis rats 
and monitoring the immune response. First, the fate of MSC injected using various routes 
was monitored in an in vivo imaging system. The biodistribution revealed a dependency 
on the injection route with MSC injected intravenously (i.v.) succumbing early after 24 h 
and MSC injected intraperitoneally (i.p.) lasting locally for at least 5 days. Importantly, no 
migration of MSC to the joint was detected in rats previously injected with PAC. MSC were 
then administered either i.v. 1 week before PAC injection or i.p. 3 weeks after to assess their 
immunomodulatory function on humoral and adaptive immune parameters. Anti-PAC IgM 
and IgG responses were detected in all PAC-injected rats with a peak at week 2 postinjec-
tion and reactivity remaining above baseline levels by week 18. IgG2a and IgG2b were the 
predominant and long-lasting IgG subtypes. By contrast, no anti-MSC antibody response 
was detected in the cohort injected with MSC only, but infusion of MSC before PAC injection 
temporarily augmented the anti-PAC antibody response. Consistent with a cellular immune 
response to PAC in PAC-injected rats, cytokine/chemokine profiling in serum by antibody 
array revealed a distinct pattern relative to controls characterized by elevation of multiple 
markers at week 2, as well as increases in proliferation in draining lymph nodes. Notably, 
systemic administration of allogeneic MSC under the described conditions did not diminish 
the immune response. IL-2 measurements in cocultures of rat peripheral blood lymphocytes 
with PAC indicated that PAC injection induced some T-cell hyporesponsiveness that was 
not enhanced in the cohorts additionally receiving MSC. Thus, PAC injected intraarticularly 
in Lewis rats induced a cellular and humoral immune response that was not counteracted 
by the systemic administration of allogeneic MSC under the described conditions.
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inTrODUcTiOn
There is a major clinical need to find curative therapies for the 
repair of articular cartilage defects secondary to trauma or dis-
eases, such as osteoarthritis (OA). The use of xenogeneic cells 
could greatly benefit the development of this treatment modal-
ity as they could be obtained in sufficient quantity following 
protocols with high quality and control (1). Notably, these cells 
could be genetically engineered to match the needs of every par-
ticular application in clinical practice (2, 3). Xenogeneic porcine 
chondrocytes are differentiated cells with the capacity to form 
hyaline cartilage in in vitro and in vivo models (4, 5). However, 
they could be potentially rejected by cellular and humoral 
mechanisms, which have not been fully characterized. The most 
relevant preclinical models for xenotransplantation of porcine 
cartilage have shown rejection in non-articular sites (6, 7). 
Subsequent studies led to the identification of key molecules and 
pathways responsible for triggering an immune response against 
porcine chondrocytes (8–10). Although their participation in 
articular cartilage rejection remains unclear, genetic engineering 
approaches could be applied to selected targets once this process 
is better understood (11). The high impact of articular cartilage 
injury and disease raises the need to consider the characteristics 
of the joint in terms of structure and immunobiology for the 
design of preclinical studies.
Mesenchymal stem cells (MSC) are the focus of research for 
cartilage repair as MSC meet many requirements for their use 
in cell therapies (12–14). MSC display immune modulation and 
promotion-of-tissue-regeneration properties. Most studies and 
clinical trials have focused on using MSC as an alternative to 
chondrocytes for direct implantation in the cartilage defect in 
combination with scaffolds or gels (12–14). However, evidence 
of superiority of these approaches over autologous chondrocyte 
implantation (ACI) or related techniques is currently lacking. ACI 
requires the harvest of cartilage from the patient for subsequent 
isolation, expansion, and transplantation of chondrocytes into 
the defect, implying limitations in cell number and quality. Thus, 
the combination of MSC and chondrocytes in situ is also being 
considered (12). Interestingly, MSC are being assessed for the 
treatment of OA in clinical trials [mostly based on intraarticular 
(i.a.) injection into the affected joint] with promising results 
(14, 15). The benefits of these MSC-based therapies for OA are 
basically attributed to their anti-inflammatory and immunosup-
pressive actions.
Mesenchymal stem cells, with some variations depending 
on the species and tissue of origin, exert immunomodulatory 
activities through multiple pathways that predominantly result 
in inhibition of both innate and adaptive immune responses 
(16–19). In particular, MSC suppress proliferation and cytokine 
release of both CD4+ and CD8+ T  lymphocytes in an MHC-
independent manner, as well as promote a shift from Th1/Th17 
toward Th2 phenotype and the generation of regulatory T cells 
(16). An inhibitory effect on B cells, NK cells, monocytes/mac-
rophages, dendritic cells, and neutrophils has also been reported 
(16). Thus, allogeneic MSC have demonstrated therapeutic 
efficacy and pose advantages versus autologous cells in terms 
of processing, quantity, and control (16). The administration 
route is also relevant for MSC to exert the immunosuppressive 
activity in vivo (19). Systemic administration is favored in cases 
of autoimmunity, graft-versus-host disease and frequently for 
facilitating tolerance of vascularized allografts (16, 18–20). 
Nevertheless, MSC administration does not always produce 
the desired tolerogenic effect as they can be also immunogenic 
depending on the setting (17, 18, 20–22).
In the present experimental study, we assessed whether 
xenogeneic porcine chondrocytes transplanted into the rat joint 
trigger an immune response. This xenotransplantation model 
was designed to provide a highly stringent setting for preclinical 
testing of future xenogeneic therapies for articular cartilage. In 
this work, we used this model to study the immunoregulatory 
effects of allogeneic MSC administered systemically as a single 
dose either 1 week before or 3 weeks after the chondrocytes.
MaTerials anD MeThODs
Porcine articular chondrocytes  
(Pac) isolation and culture
Porcine articular chondrocytes were isolated previously from 
non-transgenic pigs according to previously published methods 
(7, 10), frozen at passages 0 and 1 in DMEM mixed with 10% 
DMSO and 50% FBS (both v/v) and stored in liquid nitrogen 
until use. PAC were thawed and expanded in DMEM with 10% 
FBS (v/v), 100  IU/ml penicillin–100  mg/ml streptomycin, and 
25  µg/ml endothelial cell growth supplement (Millipore). All 
media and antibiotics were from Life Technologies and FBS from 
Biological Industries (Kibbutz Beit Haemek, Israel).
isolation, culture, genetic engineering, 
and characterization of rat Msc
Mesenchymal stem cells were isolated from bone marrow of 
14-day-old male Wistar rats (Animal Service, CHUAC) accord-
ing to previously published procedures (23). The study protocols 
were approved by the Animal Ethical Committee of Galicia. 
Briefly, the ends of femurs were cut away, and bone marrow 
was extruded by flushing with 5 ml D-Hank’s solution supple-
mented with antibiotics. Marrow suspensions were dispersed 
by pipetting, filtered and centrifuged as previously described 
(23). Cell pellets from four rats were pooled in RPMI with 10% 
FBS and antibiotics, seeded and cultured in 100-cm2 dishes 
(TM Nunclon). Adherent cells grown to 70% confluence were 
defined as passage-0 MSC and expanded for two passages for 
characterization before use (23).
Mesenchymal stem cells expressing firefly luciferase (LUC-
MSC) were generated by lentiviral infection using Lenti-X™ 
Lentiviral expression System (Clontech). Viral supernatants 
were obtained from 293 T cells transfected with pGL 4.14-Luc2 
(Promega) following standard procedures and stored at 4°C 
until transduction. MSC at 70% confluency were incubated 
sequentially with viral supernatants, washed and cultured for 
2 days before selection with 1 µg/ml puromycin (Clontech) for 
5  days. After selection, LUC-MSC were allowed to recover in 
complete media. Their function was tested in vitro by incubating 
the LUC-MSC and negative controls in phosphate-buffered saline 
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(PBS) with 150 µg/ml of firefly D-luciferin (Biosynth AG, Staad, 
Switzerland) followed by bioluminescence imaging in an IVIS 
Lumina XR imaging system using Living Image 4.3.1 software 
(Caliper Life Sciences, Waltham, MA, USA).
Inducible nitric oxide synthase (iNOS) was detected by flow 
cytometry in MSC and murine fibroblasts (3T3L1) cultured nor-
mally or after exposure to 10 ng/ml lipopolysaccharides (Sigma- 
Aldrich) for 24 h. During harvest, cells were washed with PBS 
(MP Biomedicals), then fixed in 4% paraformaldehyde (w/v) 
(Sigma-Aldrich) for 10 min, washed twice, and pre-blocked with 
2% (v/v) rat serum (Life Technologies). Cells were incubated 
with rabbit polyclonal antibody anti-iNOS (Abcam, Cambridge, 
UK) for 1 h, washed and incubated with goat anti-rabbit immu-
noglobulin-phycoerythrin (PE) (Dako, Glostrup, Denmark) 
for 1 h for measurements in a FACSAria using DIVA software 
(BD Biosciences).
animal studies
Four different animal experiments were carried out that involved 
i.a. injection of PAC into the right femorotibial joint of Lewis 
rats (summarized in Figure S1 in Supplementary Material). 
The protocols were approved by the Ethics Committee of the 
University of Barcelona and the government of Catalonia. Expe-
riments were performed following a group sequential design 
starting with a pilot with a low number of rats per group before 
proceeding with a larger study if considered appropriate (24). 
Male rats (weighing 200–250  g) were purchased from Harlan 
(Barcelona, Spain) and kept under controlled conditions of light 
and temperature with food and water ad libitum at the animal 
facilities of the University of Barcelona. Body weight and animal 
well-being were monitored throughout the study. In preparation 
for cell injection, PAC and MSC were washed thoroughly by 
centrifugation to remove the FBS, resuspended in DMEM with 
antibiotics (vehicle), and kept at room temperature. Cells were 
mixed with 15 µl of vehicle/joint for i.a. injections, 200 μl/rat for 
intraperitoneal (i.p.) injections, and 100 μl/rat for intravenous 
(i.v.) injections. All injections were performed in animals anes-
thetized with isofluorane.
For the MSC localization studies (Figure S1A in Supplementary 
Material), we used a total of 18 rats distributed in six experimen-
tal cohorts (n = 3/group). Control rats received a single injection 
with 2.5 × 106 cells/kg body weight of LUC-MSC i.a., i.v., or i.p. 
The other rats were subjected to one of three different regimes 
involving pretreatment: (1) one cohort received DMEM i.a. 
followed by i.a. injection of LUC-MSC (2.5 × 106 cells/kg body 
weight) 2.5-weeks later, (2) and (3) the others were injected i.a. 
with 3 × 106 PAC and 2.5 weeks later with the described amount 
of LUC-MSC, either i.v. or i.p. The follow-up by bioluminescence 
imaging was established at 2 and 24 h, and at 4 and 5 days after 
MSC injection in an IVIS Lumina XR imaging system using 
Living Image 4.3.1 software. For each determination, the rat was 
injected i.p. with 200  mg/kg of firefly D-luciferin and 15  min 
later was analyzed in the IVIS chamber under anesthesia with 
isofluorane.
In a pilot experiment assessing the immune response (Figure 
S1B in Supplementary Material), six male rats were equally 
distributed between two experimental groups to receive either 
PAC i.a. (cohort PAC, n = 3) or MSC i.v. and PAC i.a. (cohort 
MSC + PAC, n = 3). Injection of 3 × 106 PAC was considered time 0, 
whereas MSC (2.5 × 106 cells/kg body weight) were injected i.v. 
1 week before the PAC. The serum antibody titers were monitored 
at 2, 5, 10, and 15 weeks. Cellular responses of isolated peripheral 
blood lymphocytes (PBL) were determined by coculture assay at 
5 weeks post-PAC injection. One rat of the MSC + PAC group 
died after week 11. The loss was preceded by an arrest in growth 
that was detected at week 10, whereas the rest of rats continued 
to grow throughout the study.
In another experiment (Figure S1C in Supplementary 
Material), 22 rats were distributed between four experimental 
groups to receive either DMEM i.a. (cohort DMEM, n = 5), PAC 
i.a. (cohort PAC, n = 6), MSC i.p. (cohort MSC, n = 5) or PAC 
i.a. and MSC i.p. (cohort PAC + MSC, n = 6). Injection of 3 × 106 
PAC was considered time 0, whereas MSC (2.5 × 106 cells/kg body 
weight) were injected 3 weeks later. The immune response was 
monitored at 2, 5, 10, and 18 weeks after PAC injection by meas-
urement of serum anti-PAC antibody titers and cytokine profile 
at 2 and 5 weeks. Body weight was measured at the various time 
points. When indicated, one additional milliliter of blood was 
obtained from each of the five rats/cohort used for isolation of 
PBL and conducting coculture assays. For follow-up of the anti-
MSC antibody response, the time points were adapted to consider 
the time of MSC injection as time 0, and the 5, 10, and 18 weeks 
post-PAC injection became, respectively, 2, 7, and 15 weeks after 
MSC injection.
An additional separate study was performed with 18 rats to 
assess the immune response at the level of draining lymph nodes 
(Figure S1D in Supplementary Material), Rats were equally dis-
tributed between experimental groups to receive either DMEM 
i.a. (n = 6) and 3 × 106 PAC i.a. (n = 6) or MSC i.v. (2.5 × 106 
cells/kg body weight) 1 week before 3 ×  106 PAC i.a. (n =  6). 
Two weeks after the injection, the popliteal lymph nodes were 
harvested for lymphocyte isolation.
Detection of antibody responses
The antibody response was assessed by flow cytometry using 
PAC or MSC as target cells and rat serum diluted as indicated 
for reactivity measurements. After incubation for 30  min at 
4°C, anti-rat secondary antibodies [PE-conjugated goat F(ab′)2 
anti-rat IgM and FITC-conjugated goat F(ab′)2 anti-rat IgG 
(Beckman Coulter Inc., Fullerton, CA, USA)] were added for 
further incubation at 4°C. In a separate set of experiments, PAC 
were incubated with the same sera (at 1%) up to week 10 to 
detect the different anti-PAC IgG subtypes using anti-rat second-
ary antibodies [mouse anti-rat IgG1, IgG2a, IgG2b, and IgG2c 
mAbs-FITC (Southern Biotech Inc., Birmingham, AL, USA)]. 
In both cases, cells were finally washed with PBS and analyzed by 
flow cytometry (Beckman Coulter Gallios™, Kaluza® Analysis 
Software).
lymphocyte isolation and analysis
Peripheral blood lymphocytes were isolated from 1.5 ml of rat 
blood by Ficoll gradient followed by 2-h incubation at 37°C in 
RPMI/10% FBS to remove adherent cells. For isolation from 
TaBle 1 | IL-2 secretion by PBL isolated from PAC and MSC + PAC rats 
cultured alone or with PAC for 24 h.
Time and 
number 
of rats
cohorts il-2 (pg/ml) (mean ± seM) and condition
PBl PBl + cona PBl + Pac PBl + Pac  
+ cona
5 weeks 
(n = 3)
PAC 89 ± 35 76 ± 31 53 ± 33 118 ± 53
MSC + PAC 193 ± 68 128 ± 27 148 ± 47 274 ± 86
PBL from the indicated number of rats were isolated and cultured separately in 
triplicates. Activation of the primary signal was conducted with ConA when indicated.
MSC, mesenchymal stem cells; PAC, porcine articular chondrocytes; PBL, peripheral 
blood lymphocytes.
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lymph nodes, these were submitted to mechanical disruption 
into PBS/10% FBS and left to settle to remove large debris. 
Supernatants were transferred to clean tubes, washed by 
centrifugation and cell pellets resuspended in RPMI/10% FBS. 
In both cases, supernatants were recovered for cell counting in a 
hemocytometer in preparation for the assays.
T-cell activation was determined for individual rats in 
cocultures adapted from previously reported techniques (8, 25). 
Briefly, confluent PAC were incubated at 37°C in 96-well plates 
with PBL at 10:1 effector/target ratio. Controls of each cell type 
cultured alone were included. For additional activation, conca-
navalin A (ConA, Sigma) was added to selected wells at a final 
concentration of 10 µg/ml 30 min after initiating the coculture. 
Culture supernatants were harvested 24 h later, and IL-2 secre-
tion was measured using Rat IL-2 ELISA kit (RayBiotech, Inc., 
Norcross, GA, USA).
For characterization, isolated lymphocytes were stained with 
anti-rat CD4-FITC and CD8-FITC antibodies alone or in com-
bination with APC-conjugated anti-mouse Ki-67, PE-conjugated 
anti-Foxp3 or isotype control (all Miltenyi Biotec) for two-color 
analysis. The FoxP3 Staining Buffer Set (Miltenyi) was used for 
permeabilization and fixation. Cell surface staining of a gated 
population of lymphocytes was then measured in a Gallios flow 
cytometer.
cytokine/chemokine assays
Serum levels of 34 protein markers (Table 1) were assessed for 
most rats at baseline, week 2 and 5 postinjection by antibody 
array (Rat Cytokine Antibody Array G2, RayBiotech) with the 
technical support of tebu-bio (Le Perray-en-Yvelines, France). 
Final data corresponded to the average intensity of duplicate 
spots with the system’s background subtracted and normalized 
using internal controls.
statistical analysis
Data are presented as mean and SEM. Non-parametric statisti-
cal tests were used due to non-normal distribution of data. 
Statistical analysis was performed with the Statistical Package 
for Social Sciences (version 12.0, SPSS Inc., IL, USA) using 
Wilcoxon rank-sum test or the Mann–Whitney U test (called 
Mann–Whitney U thereafter) when comparing two groups of 
independent samples and Wilcoxon signed-rank test (called 
Wilcoxon thereafter) for the comparison between follow-up 
and baseline values. Differences were considered statistically 
significant at p ≤ 0.05.
resUlTs
Msc Distribution following Different 
administration routes
The distribution of allogeneic MSC in Lewis rats previously 
injected i.a. with PAC was firstly studied (Figure S1A in 
Supplementary Material). To this purpose, bone marrow-
derived MSC isolated from Wistar rats were genetically modi-
fied to express luciferase. These LUC-MSC, but not unmodified 
MSC, produced good bioluminescence signals when assayed 
in  vitro, which confirmed activity in the presence of luciferin 
(Figure 1A). In vivo, the biodistribution was highly dependent 
on the injection route (Figure 1B). Control rats (without PAC 
i.a.) injected with LUC-MSC i.a. showed photon signals local-
ized at the injection site for up to 5 days, although with reduced 
signal over time. No diffusion of the signal was observed for any 
of the rats in this group that would indicate leakage from the 
injection site for the first 24  h. In the other cohorts shown in 
Figure 1B, injection of PAC i.a. before MSC did not lead to MSC 
recruitment into the joint. The i.v. route led to MSC entrapment 
in the lungs with predominance of one lung over the other. The 
bioluminescence intensity was reduced by 24 h in all cases in this 
cohort and disappeared completely by day 4. On the contrary, 
MSC administered i.p. remained alive longer and were detected 
in the abdomen during the 5-day study period. Notably, no 
photon signals were observed at the joint area at any time point 
or animal following the i.v. or i.p. routes. Rats receiving MSC via 
these routes without prior PAC injection displayed an identical 
pattern (data not shown).
injection of Pac i.a. induced a Xenogeneic 
antibody response Which Was not 
reduced by Msc administered 
systemically
As a major goal in our study, we sought to assess whether i.a. 
injection of PAC induced an immune response. As a second 
objective, additional experimental groups were included to study 
the effect of MSC systemic administration. The MSC utilized 
were confirmed to express iNOS at higher proportion than fibro-
blasts in stimulated conditions (Figure S2A in Supplementary 
Material). In an initial pilot experiment, we compared the 
immune response induced in a small number of rats either 
injected i.a. with PAC only or pretreated with MSC i.v. 1 week 
before the PAC injection (MSC + PAC cohort) (Figures S1B and 
2B in Supplementary Material), An elicited anti-PAC IgM and 
IgG response was observed in all rats after i.a. injection of PAC 
(Figure 2). However, pretreatment with MSC i.v. did not reduce 
the antibody titers. In fact, the IgG antibody response may have 
been enhanced in MSC + PAC rats (Figure 2B). Likewise, MSC 
pretreatment seamed to increase overall T-cell reactivity in a 
coculture assay conducted to assess the cellular response using 
PAC and PBL isolated from each rat (Table 1). Although the low 
FigUre 1 | Distribution of allogeneic mesenchymal stem cells (MSC) in Lewis rats previously injected intraarticularly (i.a.) with porcine articular chondrocytes (PAC). 
Bioluminescence imaging was performed in an IVIS Lumina XR using Living Image 4.3.1 software. Pictures were taken with 1-min exposure to ensure detection.  
(a) Mesenchymal stem cells expressing firefly luciferase (LUC-MSC), genetically modified to express luciferase, and negative controls were incubated in phosphate-
buffered saline with firefly D-luciferin for function confirmation. (B) Follow-up of biodistribution of LUC-MSC using different injection routes as indicated. Control rats 
injected with LUC-MSC i.a. did not receive PAC, the remaining animals were injected i.a. with PAC 2.5 weeks before MSC injection (Figure S1A in Supplementary 
Material).
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sample size did not allow statistical analyses for confirmation 
of these preliminary results, we chose to stop the experiment to 
avoid using more animals with these potential undesired effects.
The main experiment was designed to study the immune 
response to PAC-injected i.a. compared with a cohort receiv-
ing vehicle alone (DMEM), as well as the effect of MSC on 
this response once initiated (Figure S1C in Supplementary 
Material). To this end, MSC were administered i.p. 3 weeks after 
PAC injection in a PAC + MSC cohort. Notably, no deleterious 
effects were observed for any of the treatments (PAC or MSC) on 
the well-being and body weight of the animals throughout this 
experiment (Figure S2C in Supplementary Material). To monitor 
the humoral response, anti-PAC antibody titers were determined 
in all cohorts up to 18 weeks. Anti-MSC antibody reactivity was 
also measured for the DMEM and MSC cohorts. The cellular 
response was studied by assessing the serum cytokine/chemokine 
profile and setting up coculture assays with PBL isolated from 
each rat at selected time points.
Notably, no anti-MSC antibody (IgM or IgG) reactivity was 
detected in sera of rats injected with MSC over controls for 
the duration of the study (up to 15 weeks after MSC injection) 
(Figure 3).
Anti-PAC IgM and IgG responses were detected by flow 
cytometry in all rats injected with PAC but not in controls 
(DMEM and MSC cohorts) (Figure  4). Both anti-PAC IgM 
and IgG showed the highest reactivity at week 2 (first measure-
ment after baseline) and diminished slowly afterward, although 
remained above baseline levels by week 18. No effect of the MSC 
(injected at week 3) was observed on the antibody response 
(Figures 4C,F). The elicited antibodies were further character-
ized in the cohorts injected with PAC i.a. by measuring the anti-
PAC IgG subtypes (Figure 5). The profiles for rats injected with 
or without MSC were identical. The four IgG subtypes increased 
after PAC injection, although with different patterns. Changes in 
anti-PAC IgG1 and IgG2c followed the same timing of transient 
elevations at week 2 followed by dramatic decreases afterward. 
FigUre 3 | Antibody response in Lewis rats injected intraperitoneally (i.p.) 
with mesenchymal stem cells (MSC). The study included samples from the 
DMEM and MSC cohorts described in Figure S1C in Supplementary Material. 
In particular, the MSC cohort was injected i.p. with MSC and followed-up for 
15 weeks at the indicated time points in this figure, whereas the control cohort 
was injected with DMEM i.a. 5 weeks before the 2-week time point. Anti-MSC 
IgM (a) and IgG (B) antibody reactivity was determined by flow cytometry for 
all rat sera (0.6% final dilution) collected at baseline and at 2, 7, and 15 weeks 
after MSC injection. The mean ± SEM of mean FL-1 fluorescence intensity 
after subtracting the background (reactivity of secondary antibody alone) is 
shown (n = 5). No significant differences were detected when results of the 
two cohorts were compared using the Mann–Whitney U test.
FigUre 2 | Antibody response in Lewis rats injected intraarticularly (i.a.) with 
porcine articular chondrocytes (PAC) only or pretreated with mesenchymal 
stem cells (MSC) intravenously (i.v.). A scheme of the experimental design is 
shown in Figure S1B in Supplementary Material. In particular, one cohort 
received only PAC i.a., whereas the other cohort was injected with MSC i.v. 
1 week before PAC i.a. injection (MSC + PAC) and both followed-up for 
15 weeks. Anti-PAC IgM (a) and IgG (B) antibody reactivity was determined 
by flow cytometry for all rat sera (0.6% final dilution) collected at baseline and 
at 2, 5, 10, and 15 weeks after PAC injection. The mean ± SEM of mean 
FL-1 fluorescence intensity after subtracting the background (reactivity of 
secondary antibody alone) is shown (n = 3 for PAC and MSC + PAC 
cohorts).
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On the contrary, anti-PAC IgG2a peaked at 5 weeks and remained 
high at 10 weeks, whereas anti-PAC IgG2b remained high after 
the first increase at week 2.
injection of Pac i.a. induced a Xenogeneic 
cellular immune response Which Was 
not influenced by Msc administered  
after 3 Weeks
Serum levels of 34 proteins were assessed by antibody array 
(Table  2) in 32 samples from individual rats of the DMEM, 
PAC, and PAC +  MSC cohorts including at baseline and at 2 
and 5  weeks. No differences were observed for most proteins 
tested, but results corresponding to 12 markers associated 
with inflammation and T-cell responses (activin A, fractalkine, 
GM-CSF, ICAM-1, IFN-γ, IL-1α, IL-2, IL-4, IL-10, L-selectin, 
MIP-3α, and TIMP-1) seemed potentially modified by the treat-
ments (Figure  6) and were further evaluated. Thus, data from 
the PAC and PAC + MSC cohorts at baseline and week 2 were 
combined because an identical protocol was applied before week 
3. Results and statistical analyses of the data pooled (n = 8) and 
shown for 10 of these proteins in Table 3 allowed to appreciate 
FigUre 4 | Antibody response in Lewis rats injected intraarticularly (i.a.) with porcine articular chondrocytes (PAC) only or posttreated with mesenchymal stem cells 
(MSC) intraperitoneally (i.p.). A scheme of the experimental design comprising four different groups is shown in Figure S1C in Supplementary Material. In particular, 
one cohort received only DMEM i.a., another only PAC i.a., another was injected with MSC i.p. 3 weeks after PAC i.a. injection, whereas the corresponding control 
received only MSC i.p. at the same time. All were followed-up for 18 weeks. Anti-PAC IgM (a–c) and IgG (D–F) antibody reactivity was determined by flow 
cytometry for all rat sera (0.5% final dilution) collected at baseline and at 2, 5, 10, and 18 weeks after PAC injection. The mean ± SEM of mean FL-1 fluorescence 
intensity after subtracting the background (reactivity of secondary antibody alone) is shown (n = 5 for DMEM and MSC cohorts; n = 6 for PAC and PAC + MSC 
cohorts). Statistically significant differences were observed using the Mann–Whitney U test for the 2-week time point, but not the baseline, for both IgM and IgG 
relative to corresponding levels of the control cohort (ap < 0.01, bp < 0.005). No significant differences were detected when results of the PAC and PAC + MSC 
cohorts were compared using the Mann–Whitney U test (c,F).
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a distinct pattern between the DMEM group and the cohorts 
receiving PAC. Whereas most of these selected markers remained 
unchanged or even diminished in the vehicle-injected cohort, 
there was a profile associated with increases in serum marker 
levels after PAC injection at week 2 (Figure 6; Table 3). By week 
5 postinjection, all these proteins had returned to baseline levels 
FigUre 5 | Changes in IgG antibody subtypes in Lewis rats injected intraarticularly (i.a.) with porcine articular chondrocytes (PAC) only or posttreated with 
mesenchymal stem cells (MSC) intraperitoneally (i.p.). The study included samples from the PAC and PAC + MSC cohorts collected at baseline, 2, 5, and 10 weeks 
after PAC injection (Figure S1C in Supplementary Material). In particular, the PAC cohort received only PAC i.a., whereas the PAC + MSC rats were injected with 
MSC i.p. 3 weeks after PAC i.a. injection. Anti-PAC IgG1, IgG2a, IgG2b, and IgG2c antibody reactivity was determined by flow cytometric analysis in sera of all 
experimental rats at 1%. The mean FL-1 fluorescence intensity after subtracting the background (reactivity of secondary antibody alone) is shown as mean ± SEM 
for the PAC and PAC + MSC cohorts (n = 6). Statistically significant differences were observed using the Wilcoxon test for the assessed time points and subtypes 
relative to corresponding baseline levels as indicated (ap ≤ 0.05). No significant differences were observed using the Mann–Whitney U test when comparing results 
from the PAC and PAC + MSC cohorts.
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with exception of fractalkine (Figure 6). IL-2 and L-selectin were 
significantly elevated 2  weeks after PAC injection (p =  0.036, 
n  =  8). Nonetheless, IL-1α was also significantly elevated, 
whereas GM-CSF and ICAM-1 showed similar trends toward 
significance. The effect of MSC on the markers was less clear, 
but it was still of interest to compare the profiles of the PAC and 
PAC + MSC cohorts at 2 and 5 weeks to assess the presence of 
some counteractive trends (Figure 6).
Coculture assays were set with PAC and PBL isolated from 
these rats at 2 and 10  weeks postinjection for IL-2 measure-
ments (Table 4). This type of coculture provided information on 
the level of T-cell activation and co-stimulatory capacity (with 
ConA) in the presence and absence of PAC. The data showed for 
most rats and time points that there was some T-cell reactivity 
after coculture with PAC, which was further enhanced in the 
presence of ConA. Interestingly, the amount of IL-2 secreted 
in coculture was lower for PBL from PAC-injected rats than in 
those not exposed to PAC, although the co-stimulatory signals 
were preserved (elevations with ConA). Moreover, rats injected 
with MSC alone showed a profile very similar to the PAC cohort. 
Nevertheless, no major differences were observed between the 
PAC and PAC + MSC cohort at this level that could indicate an 
TaBle 2 | Proteins identified in RayBio® rat cytokine antibody array G2.
symbol Full protein name
Activin A Inhibin beta A chain, homodimer
Agrin Agrin
CD86 (B7-2) CD86 antigen
Beta-NGF Beta-nerve growth factor
CINC-1 Chemokine (C–X–C motif) ligand 1 (CXCL1)
CINC-2 Chemokine (C–X–C motif) ligand 3 (CXCL3)
CINC-3 Chemokine (C–X–C motif) ligand 2 (CXCL2)
CNTF Ciliary neurotrophic factor
FasL Fas ligand (CD178, CD95L, TNFSF6) 
Fractalkine Fractalkine (CX3CL1)
GM-CSF Granulocyte-macrophage colony-stimulating factor (CSF2)
ICAM-1 Intercellular adhesion molecule 1 (CD54)
IFN-gamma Interferon gamma
IL-1 alpha Interleukin-1 alpha (IL-1 F1)
IL-1 beta Interleukin-1 beta (IL-1 F2)
IL-1 R6 Interleukin-1 receptor-like 2 (IL-1 Rrp2)
IL-2 Interleukin-2
IL-4 Interleukin-4
IL-6 Interleukin-6
IL-10 Interleukin-10
IL-13 Interleukin-13
Leptin Leptin (LEP)
LIX Chemokine (C–X–C motif) ligand 5 (CXCL5)
L-Selectin L-selectin (CD62L)
MCP-1 Chemokine (C–C motif) ligand 2 (CCL2)
MIP-3 alpha Chemokine (C–C motif) ligand 20 (CCL20)
MMP-8 Matrix metalloproteinase-8
PDGF-BB Platelet-derived growth factor subunit B (PDGFB)
Prolactin R Prolactin receptor
RAGE Advanced glycosylation end product-specific receptor
TCK-1 Chemokine (C–X–C motif) ligand 7 (CXCL7)
TIMP-1 Metalloproteinase inhibitor 1
TNF alpha Tumor necrosis factor alpha
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additional beneficial effect provided by MSC injected 3  weeks 
after PAC (Table 4, week 10). Very similar results were obtained 
when we analyzed PBL from three rats collected at week 5 of the 
experiment (data not shown).
In a final study, rats received either DMEM i.a., PAC i.a. or 
MSC i.v. 1 week before PAC i.a. to assess the cellular immune 
response at the level of draining lymph nodes 2  weeks after 
injection (Figure S1D in Supplementary Material). The mean 
(±  SEM) number of total lymphocytes after isolation were, 
respectively, 2.7 ± 0.37 and 2.87 ± 0.35 million for the PAC and 
MSC + PAC cohorts versus 0.98 ± 0.07 million for the DMEM 
cohort (p = 0.004 for both). Flow cytometric analysis showed that 
the percentage of CD4+ and CD8+ lymphocytes remained within 
the same range for all cohorts (Figure 7A), although CD4+ cells 
showed a higher proliferation as detected by Ki-67 staining 
2  weeks after PAC injection (Figures  7B,C). The percentage 
of Foxp3 cells was not clearly increased after PAC injection 
(Figure 7C), although most rats pretreated with MSC had higher 
numbers of these cells (Figure 7C).
DiscUssiOn
In this study, a discordant xenotransplantation model by injecting 
PAC into the femorotibial joint of Lewis rats was established. 
A relatively high dose of PAC was chosen considering the 
amount used for ACI (13, 26) and in previous animal models 
(5, 27) to generate a setting of high stringency for subsequent 
testing of immunomodulatory strategies. Notably, this proce-
dure triggered a cellular and antibody response, implying that 
this simple model may provide valuable preclinical information 
for the development of xenogeneic therapies for articular carti-
lage repair. Particularly, it allows assessing strategies intended 
to modify the immune response such as the procedures studied 
here based on systemic administration of bone marrow-derived 
MSC. Conversely, it is not conceived for assessing cartilage 
reconstruction. Previous models of articular cartilage repair 
using other species combinations provided mixed results (5, 27, 
28). Isolated PAC implanted into a partial chondral defect in 
rabbits did not induce a cellular immune infiltrate (5). However, 
rejection was confirmed in a cow-to-rabbit combination when 
in  vitro engineered constructs were transplanted into full-
thickness lesions subjected to microfracture (28). Furthermore, 
human articular chondrocytes failed to engraft when trans-
planted into knee defects in minipigs (27). Of note, none of these 
studies evaluated antibody response. In comparison, our model 
provides information at both the cellular and antibody levels in 
a discordant combination with preclinical value.
Intraarticular injection of PAC elicited an anti-PAC IgM 
and IgG response, with a peak at week 2 postinjection and 
predominance of IgG2a and IgG2b subtypes that persisted 
over time. Notably, rat IgM and IgG2b are potent inducers of 
complement activation and known to contribute to xenograft 
rejection of solid organs (29). The transient increase in IgG2c 
may also participate at this level. We have also determined a 
role of antibody and complement in PAC activation and trig-
gering an immune response through upregulation of adhesion 
molecules and cytokine release (10, 11). Regarding their effect 
on innate cellular immune responses, IgG2a and IgG2b display 
the strongest effector functions in mice (30). Although we found 
no information about the affinity of rat IgG subclasses to the 
various Fc receptors, rat IgG2a and IgG2b show around 80% 
sequence similarity with the mouse counterparts and 92% for 
IgG1. Thus, it can be argued that this antibody binding would 
facilitate the response to PAC by macrophages (that express all 
activating Fc receptors) and antibody-dependent cell-mediated 
cytotoxicity by NK  cells (expressing FcγRIII). Moreover, the 
predominance of both IgG2a and IgG2b subtypes indicates the 
presence of both Th1 and Th2 T cells and associated cytokines. 
In rats, it is known that Th2 cytokines (IL-4) promote IgG1 
and IgG2a responses, whereas Th1 cytokines (IL-12 and IFNγ) 
stimulate the production of IgG2b and IgG2c (31).
The cytokine/chemokine profiling in serum provided evi-
dence of an active cellular response characterized by elevation 
of multiple markers at 2  weeks. IL-1α, IL-2, and L-selectin 
reached significance, whereas other markers showed trends. 
IL-1 cytokines are produced by monocytes and neutrophils and 
effect potent pro-inflammatory activity through vasodilatation, 
recruitment, and activation of immune cells, as well as promo-
tion of matrix degradation (32). Interestingly, serum L-selectin, 
being generated mostly by shedding, is gaining attention as a 
marker of cell activation (33). Likewise, ICAM-1 is released to 
FigUre 6 | Serum levels of selected markers assessed by antibody array in Lewis rats injected intraarticularly (i.a.) with porcine articular chondrocytes (PAC)  
only or posttreated with mesenchymal stem cells (MSC) intraperitoneally (i.p.). The study included samples from three of the cohorts described in Figure S1C in 
Supplementary Material. In particular, one cohort received only DMEM i.a., another only PAC i.a., and the last one was injected with MSC i.p. 3 weeks after  
PAC i.a. injection (PAC + MSC). Results are presented in reference units. Determinations were done in samples from the DMEM (baseline and 2 weeks, n = 3 each), 
PAC and PAC + MSC cohorts (baseline and at 2 and 5 weeks after PAC injection, n = 5 for PAC and n = 3/4 for PAC + MSC). Each eight-sample array included 
samples for all time points from the same individual, with the exception of one baseline sample from the PAC + MSC group, and assessed rats from different 
cohorts. Thus, each animal within one cohort is depicted with the same symbol and can be followed over time. The bars represent the mean.
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TaBle 3 | Serum levels of selected markers assessed by antibody array in Lewis 
rats injected i.a. with PAC.
Biomarker cohort and time
DMeM 
baseline
DMeM Paca Paca
2 weeks baseline 2 weeks
GM-CSF 937 ± 36 839 ± 113 943 ± 77 1,049 ± 99b
ICAM-1 11,190 ± 649 5,749 ± 1,588 9,320 ± 1,531 10,678 ± 1.679c
IFN-γ 159 ± 10 173 ± 53 209 ± 34 259 ± 48
IL-1α 1,616 ± 29 1,474 ± 250 1,966 ± 354 2,989 ± 984d
IL-2 1,779 ± 77 1,609 ± 285 2,019 ± 334 2,757 ± 692d
IL-4 1,529 ± 19 1,329 ± 189 1,714 ± 143 1,919 ± 243
IL-10 1,192 ± 47 936 ± 129 1,388 ± 194 1,737 ± 387
L-selectin 7,288 ± 661 6,125 ± 211 5,831 ± 630 7,585 ± 859d
MIP-3α 1,635 ± 38 1,547 ± 207 1,943 ± 360 2,708 ± 803
TIMP-1 4,957 ± 1,136 4,867 ± 2,586 4,321 ± 1,346 63,74 ± 2,060
Data from the PAC and PAC + mesenchymal stem cells (MSC) cohorts were  
combined because an identical protocol was applied before week 3. Results  
are presented as mean ± SEM of the array reference units.
aData correspond to the PAC and PAC + MSC cohorts pooled together (n = 8)  
and compared with baseline levels by Wilcoxon signed-rank test.
bStatistical analysis versus baseline values, p = 0.069.
cStatistical analysis versus baseline values, p = 0.09.
dStatistically significant versus baseline values, p ≤ 0.05 for IL-2, L-selectin, and IL-1α.
PAC, porcine articular chondrocytes.
TaBle 4 | IL-2 secretion by PBL isolated from experimental rats cultured alone 
or with PAC for 24 h.
Time and 
number  
of rats
cohorts il-2 (pg/ml) (mean ± seM) and condition
PBl PBl + cona PBl + Pac PBl + Pac  
+ cona
2 weeks  
(n = 5)
DMEM 77 ± 28 315 ± 29 455 ± 64 846 ± 136
PAC 103 ± 36 271 ± 115 146 ± 68a 584 ± 138
10 weeks  
(n = 5)
DMEM 75 ± 22 405 ± 35 371 ± 68 581 ± 60
PAC 130 ± 33 271 ± 27b 216 ± 89b 484 ± 55
MSC 61 ± 28 372 ± 48 203 ± 58c 492 ± 82
PAC + MSC 52 ± 28 301 ± 46 194 ± 36c 509 ± 44
PBL from the indicated number of rats were isolated and cultured separately in 
triplicate. Activation of the primary signal was performed with ConA when indicated.
Statistically significant differences were analyzed with the Mann–Whitney U test. 
Significance was attained for the indicated conditions relative to corresponding 
determination in the DMEM cohort.
ap ≤ 0.01.
bp ≤ 0.05.
cp ≤ 0.02.
No significant differences were observed between the corresponding determinations  
of the PAC + MSC cohort and the PAC or MSC alone cohorts.
MSC, mesenchymal stem cells; PAC, porcine articular chondrocytes; PBL,  
peripheral blood lymphocytes.
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circulation by shedding, whereas TIMP-1 plays the opposite role 
by controlling the activity of matrix metalloproteinases (34). The 
increase in GM-CSF is also of interest as it reflects the promotion 
of myeloid activity including the maturation of pro-inflammatory 
macrophages (35). Finally, the serum IL-2 augment (character-
istic of T-cell activation) paralleled the higher cellularity and 
proliferation in draining lymph nodes. Non-significant increases 
in IFNγ, IL-4, and IL-10 were consistent with a balanced Th1/Th2 
response in this setting. Most markers shown in Table 2 shared a 
pro-inflammatory profile.
Cocultures of PAC with PBL isolated from rats without 
prior exposure to PAC produced some IL-2 secretion that 
was further enhanced by ConA. The costimulatory molecule 
CD86 expressed on PAC (8) may be the main trigger for T-cell 
acti vation in the presence of ConA. Notably, PBL from PAC- 
injected rats displayed some degree of T-cell hyporesponsive-
ness. This finding is consistent with recent experiences reporting 
the capability of chondrocytes to favor immune regulation and 
privilege through various pathways (36–38). Thus, production 
of nitric oxide and induction of indoleamine 2,3-dioxigenase 
contributed to this effect (36, 38). Moreover, we found no clear 
increase in regulatory T cells after PAC injection that could lead 
to hyporesponsiveness. Although xenogeneic chondrocytes are 
more immunogenic than allogeneic and autologous chondro-
cytes (28), they probably share some (if not all) the tolerogenic 
pathways of autologous chondrocytes. Thus, genetic engineer-
ing of PAC may allow reducing the immunogenic molecules 
while preserving the immune privilege capabilities.
Systemic administration of allogeneic MSC under the two 
selected conditions, both based on single injections, did not 
prevent or reduce cellular and antibody responses against PAC. 
Furthermore, T-cell hyporesponsiveness was not enhanced in 
the cohorts additionally receiving MSC. The time points of 
MSC injection chosen for this work aimed to avoid the high-
est peak of inflammation and the potential deleterious effects 
as previously described for solid organ allotransplantation 
(20, 39–41). In fact, Merino et  al. have recently shown in 
the same Wistar-to-Lewis rat combination that a full week is 
needed for MSC infused i.v. to generate an anti-inflammatory 
environment (41). Accordingly, pretreatment with MSC 7 days 
before renal allotransplantation protects better from acute 
graft rejection than when MSC are infused 4  days before 
transplant (41). The dose of MSC was also selected based on 
previous data reported in transplant studies in Lewis rats 
(39, 42). Moreover, the MSC were administered i.p. for the 
main experiment because the commonly used i.v. route led to 
short-lived MSC, which died entrapped in the lung capillaries 
(43, 44). By contrast, the MSC administered i.p. survived much 
longer and displayed even higher intensity than those injected 
i.a. Although less frequently used, the i.p. administration of 
bone marrow-derived MSC was reported to be protective in 
a model of collagen-induced arthritis (45). We acknowledge 
that there is no information of superiority of the i.p. route over 
the i.v. administration. Nevertheless, the relevance of these 
differences should be taken with caution considering how they 
can be translated into clinical practice. Importantly, none of 
the animals injected with MSC outside the joint, either i.v. or 
i.p., showed MSC migration to the PAC-injected joint, which 
is similar to results obtained in arthritis mouse models (46).
Some hyporesponsiveness in the MSC control group (injected 
i.p.) was detected as compared with the vehicle-injected control, 
whereas the MSC injected i.v. 1 week before PAC increased the 
presence of Foxp3-positive lymphocytes in draining lymph 
nodes. Moreover, expression of iNOS was also confirmed in 
these cells, discarding any defect in our MSC preparation. The 
efficacy of allogeneic MSC administered i.p. was also related 
to T-cell hyporesponsiveness, modulation of inflammatory 
FigUre 7 | Analysis of CD4+ and CD8+ lymphocytes isolated from draining lymph nodes from Lewis rats injected intraarticularly (i.a.) with porcine articular 
chondrocytes (PAC) only or pretreated with mesenchymal stem cells (MSC) intravenously (i.v.). A scheme of the experimental design is shown in Figure S1D  
in Supplementary Material. In particular, one cohort received only DMEM i.a. as control, another only PAC i.a., and the MSC + PAC was injected with MSC i.v. 
1 week before PAC i.a. injection. Flow cytometric two-color analysis of lymphocytes isolated 2 weeks after PAC injection allowed determination of the 
proportion of CD4+ and CD8+ cell populations (a) and the percentage proliferating by ki-67 expression (B) presented as mean ± SEM (n = 6). Statistically 
significant differences were observed using the Mann–Whitney U test for the percentage of CD4+ki-67+ cells relative to the corresponding control cohort 
(ap ≤ 0.05), but not for the rest of parameters analyzed. Although only CD4+ lymphocytes showed higher proliferation in the PAC-injected cohorts, the 
proliferation of CD8+ T cells may have taken place earlier as it remained in comparable proportion in all cohorts. (c) Representative dot plots of anti-CD4 
staining in combination with anti-ki-67, anti-Foxp3, and IgG1 control for each cohort (n = 6). Numbers indicate the percentage of cells in the upper right 
quadrant relative to total counts.
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cytokines, and increased activity of regulatory T  cells in the 
collagen-induced arthritis model (45). Similar observations 
applied to various animal models of autoimmune disease (18), 
solid organ, and corneal allotransplantation (20, 47) after infu-
sion of MSC. Thus, the stronger immune response triggered by 
xenografts relative to allografts may explain why MSC failed to 
potentiate this effect when used in combination with PAC. The 
fact that we observed a potential enhancement of the immune 
response with a regime (MSC i.v. day −7) that had previously 
been described as protective in an allogeneic transplant setting 
(40, 48) indicated a differential outcome in xenotransplantation. 
A possible explanation for these results would be that some 
pro-inflammatory events triggered by the infusion of allogeneic 
MSC amplify the xenogeneic immune response against PAC. 
In accordance with higher requirements of immune regulation 
in the xenogeneic setting, local application of allogeneic MSC 
failed to prolong survival of corneal xenografts in a pig-to-rat 
model (48), whereas protection has been described for corneal 
allografts (47). Nevertheless, this is a concept that has to be dem-
onstrated in well designed experiments that study in parallel the 
outcome of equivalent allografts and xenografts in well defined 
settings. Furthermore, the fact that MSC and PAC share some 
tolerogenic pathways (38) may also contribute. This is also a new 
hypothesis that is worth considering for future work. Additional 
immunoregulatory properties of MSC such as promotion of 
regulatory T cells (16, 20, 47) also remain to be clarified in this 
setting (49).
Finally, we cannot discard without further experimentation 
that a higher dose of MSC or a different administration regime 
(i.e., MSC administration a few days to a week after PAC injec-
tion or repeated MSC injection) might exert a stronger immu-
nosuppressive effect. A single injection of allogeneic MSC did 
not induce a specific antibody response, indicating that an addi-
tional dose could be applied. This finding could be associated to 
this specific allogeneic combination (Wistar-to-Lewis) as other 
groups have reported the induction of antibodies after allogeneic 
MSC administration in other animal models including healthy 
rats (22). Nevertheless, the immunoregulatory capabilities of 
MSC also include inhibition of plasmablast formation and the 
associated antibody generation (50). Technical aspects regard-
ing the detection of the elicited alloantibodies may also have 
influenced. Here, we used for detection of antibody reactivity, as 
target cells, the same MSC used for injection in the in vivo studies. 
In any case, we do agree that future work should continue to 
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include measurement of anti-donor MSC antibodies as this 
could be a factor to impact on the efficacy of MSC-based 
therapies.
cOnclUsiOn
In this work, we demonstrate that PAC-injected i.a. in Lewis rats 
induces a cellular and humoral immune response. Considering 
previous studies, this is not an expected result. Interestingly, the 
allogeneic MSC administered systemically as a single injection 
in control healthy rats caused some T-cell hyporesponsiveness 
to PAC and did not induce an anti-MSC antibody response. 
Nevertheless, the two conditions used here for MSC delivery dif-
ferentially affected but did not prevent the cellular and humoral 
immune responses triggered by i.a. injection of PAC. Finally, this 
rat model allows assessing additional protocols and genetic engi-
neering strategies for the development of xenogeneic cell-based 
therapies for cartilage repair.
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